Keynote Sessions
One Statistician's View of the Important Contributions of Statisticians to the Past 50 Years of Oncology Clinical Trials
Speaker: Scott S. Emerson, University of Washington
Scott S. Emerson, M.D., Ph.D., is Professor Emeritus of Biostatistics at the University of Washington. Dr. Emerson holds a B.A. in physics, an M.D., and a Master's degree in computer science from the University of Virginia and a Ph.D. in Biostatistics from the University of Washington. He previously held faculty positions in the Department of Statistics at the University of Florida and in the Department of Statistics and Arizona Cancer Center at the University of Arizona. Dr. Emerson is active in research into methods for the design, conduct, and analysis of clinical trials, especially related to the use of sequential and adaptive methods, both frequentist and Bayesian. He served as a member of the National Academies of Science Oversight Committee for Missing Data in Clinical Trials, multiple FDA Advisory Committees, and numerous government and industry DSMBs and RCT steering committees. He is a Fellow of the American Statistical Association.
Abstract
TBA
Dose Optimization of Early Phase Clinical Trials
Speaker: Patricia LoRusso, D.O., Yale Cancer Center
Dr. Patricia LoRusso has been a practicing academic medical oncologist performing clinical/translational research in early phase clinical trials for 30 years. She has served on the Board of Directors and numerous scientific and education committees of the American Association for Cancer Research, the education and scientific committees of the American Society of Clinical Oncology, and the steering committee for the Food and Drug Administration, Accelerating Anticancer Agent Development and Validation Workshop. She has taught several clinical trials educational workshops, educating many physicians and scientists across the globe. She has worked closely with Cancer Research United Kingdom. She is currently serving a 3-year term as the chair of their New Agents Committee, reviewing international proposals relative to drug development of novel agents. Working closely with patients suffering from advanced malignancies, Dr. LoRusso has become an advocate, not only for cancer researchers and clinicians, but more importantly for the patients and their caregivers. Having experienced at a young age the death of her own parents from cancer, she understands the urgent need for new cancer discoveries and the potential for longevity and quality of life.
Abstract
TBA